Based on the hollow fiber assay (HFA) developed by theĀ  USNational Cancer Institute (NCI), and combined with the novel Microtube Array Membrane (MTAM) delivers anti-cancer drug solutions for personalized cancer treatment and commercial anti-cancer drug R&D. Our screening range of services brings unprecedented accuracy and translatability, at a fraction of the time and cost of conventional screening solutions.



Next generation rapid and reliable anti-cancer drug screening platform for Personalized Medicine

Learn More


High throughput, extremely rapid, excellent translatability and cost effective candidate drug molecule screening platform for your drug research and developmentĀ 

Learn More


High translatability and rapid screening of target patient segment identification for your lead candidate drug

Learn More